Advertisement

Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes

  • Chia-Hsien ChangEmail author
  • Motonobu Sakaguchi
Original Article
  • 36 Downloads

Abstract

Objectives

To identify the association of type 2 diabetes (T2DM) and liver disease with elevated ALT and factors associated with increased ALT in patients with and without T2DM.

Design and setting

We performed a retrospective study in adults with ≥ 2 claims for blood tests recorded in the Medical Data Vision claims database between 2010 and 2016.

Participants

Patients were entered into T2DM and non-DM groups based on diagnosis and medication claim codes.

Primary outcome measure

The primary endpoint was the first follow-up ALT elevation over three times the normal value, and etiologies were categorized by subsequent diagnoses. We estimated the ALT elevation incidence and association with T2DM using Poisson regression and Cox proportional hazard models.

Results

We identified 3161 cases of elevated ALT in 104,903 patients (follow-up, 280,659 patient-years). The age- and sex-adjusted incidence of elevated ALT in the T2DM group (13.47 per 1000 patient-years; 95% confidence interval (CI) 12.53–14.48) was significantly higher than that in the non-DM group (8.43 per 1000 patient-years; 95% CI 7.72–9.20, p < 0.0001). Compared to the non-DM group, the T2DM group had an approximately 3.5 times higher risk of fatty liver-related ALT elevation (adjusted hazard ratio (HR), 3.54; 95% CI 1.90–6.58). T2DM was not associated with an increased incidence of jointly elevated ALT and total bilirubin (adjusted HR, 0.94; 95% CI 0.77–1.15).

Conclusion

T2DM is strongly associated with increased liver enzymes secondary to fatty liver. The causes of liver enzyme abnormalities were not fully characterized due to a high proportion of unexplained ALT elevation.

Keywords

Alanine transaminase Diabetes mellitus Epidemiology Japan Liver diseases 

Notes

Acknowledgements

We would like to thank Editage (http://www.editage.com) for editing and reviewing this manuscript for English language.

Author contribution

All authors contributed to the conceptualization of the study and preparation of the manuscript, including literature review (CHC), data analysis (CHC) and result interpretation (CHC and MS), and are responsible for the reported research. All the authors have read the manuscript and approved its submission.

Funding

This work was supported by Takeda, Japan.

Compliance with ethical standards

Conflicts of interest

CHC and MS are employees of Takeda. The authors declare they have no conflict of interest with respect to this research study and paper. The funder (Takeda, Japan) provided support in the form of salaries for authors (CHC, MS) and research materials only, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics policy

As secondary database we used for research purposes contained anonymized data only, this article does not contain any studies with human or animal subjects performed by any of the authors. Patient informed consent was not required, because it is impossible to link the identifiers with external information.

Supplementary material

13340_2019_405_MOESM1_ESM.docx (39 kb)
Supplementary material 1 Table. S1 Disease categories and diagnosis codes used to determine the causes of ALT elevation identified in the Medical Data Vision database (DOCX 38 kb)

References

  1. 1.
    Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Public Policy Committee of the American Association for the Study of Liver D. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.CrossRefGoogle Scholar
  2. 2.
    Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. 2005;71:1105–10.Google Scholar
  3. 3.
    Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.CrossRefGoogle Scholar
  4. 4.
    Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95.CrossRefGoogle Scholar
  5. 5.
    Miyake Y, Eguchi H, Shinchi K, Oda T, Sasazuki S, Kono S. Glucose intolerance and serum aminotransferase activities in Japanese men. J Hepatol. 2003;38:18–23.CrossRefGoogle Scholar
  6. 6.
    Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring). 2007;15:1841–50.CrossRefGoogle Scholar
  7. 7.
    Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, et al. Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. Metabolism. 2009;58:1067–75.CrossRefGoogle Scholar
  8. 8.
    Kramer CK, Retnakaran R. Liver enzymes and type 2 diabetes: a complex two-way relationship. J Diabetes Complicat. 2013;27:301–2.CrossRefGoogle Scholar
  9. 9.
    Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–48.CrossRefGoogle Scholar
  10. 10.
    Morling JR, Fallowfield JA, Guha IN, Williamson RM, Ali M, Glancy S, et al. Clinically significant chronic liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. QJM. 2016;109:249–56.CrossRefGoogle Scholar
  11. 11.
    Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–7.CrossRefGoogle Scholar
  12. 12.
    Saeed MJ, Olsen MA, Powderly WG, Presti RM. Diabetes mellitus is associated with higher risk of developing decompensated cirrhosis in chronic hepatitis C patients. J Clin Gastroenterol. 2017;51:70–6.CrossRefGoogle Scholar
  13. 13.
    Marcinak JF, Munsaka MS, Watkins PB, Ohira T, Smith N. Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug Saf. 2018;41:625–40.CrossRefGoogle Scholar
  14. 14.
    Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–15.CrossRefGoogle Scholar
  15. 15.
    Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633–40.CrossRefGoogle Scholar
  16. 16.
    Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRefGoogle Scholar
  17. 17.
    Morling JR, Strachan MW, Hayes PC, Butcher I, Frier BM, Reynolds RM, et al. Prevalence of abnormal plasma liver enzymes in older people with type 2 diabetes. Diabet Med. 2012;29:488–91.CrossRefGoogle Scholar
  18. 18.
    Hashikata H, Harada KH, Kagimura T, Nakamura M, Koizumi A. Usefulness of a large automated health records database in pharmacoepidemiology. Environ Health Prev Med. 2011;16:313–9.CrossRefGoogle Scholar
  19. 19.
    Harvey R, Jankus DD, Mosley D. Random assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS®. 2012. https://www.mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdf. Accessed 6 Feb 2017.
  20. 20.
    US Department of Health and Human Services FDaA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry druginduced liver injury: premarketing clinical evaluation. 2009. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation Accessed 28 Feb 2017.
  21. 21.
    Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.CrossRefGoogle Scholar
  22. 22.
    Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149:1731–41.CrossRefGoogle Scholar
  23. 23.
    Makar GA, Weiner MG, Kimmel SE, Bennett D, Burke A, Yang YX, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008;17:43–51.CrossRefGoogle Scholar
  24. 24.
    Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–5.CrossRefGoogle Scholar
  25. 25.
    Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.CrossRefGoogle Scholar
  26. 26.
    Ulcickas Yood M, Bortolini M, Casso D, Beck JG, Oliveria SA, Wells KE, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015;24:427–34.CrossRefGoogle Scholar
  27. 27.
    Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol. 1997;146:565–71.CrossRefGoogle Scholar
  28. 28.
    Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109:588–90.CrossRefGoogle Scholar
  29. 29.
    Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population. J Clin Gastroenterol. 2017;51:160–6.CrossRefGoogle Scholar
  30. 30.
    Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol. 2017;9:679–88.CrossRefGoogle Scholar
  31. 31.
    Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–9.CrossRefGoogle Scholar
  32. 32.
    Shafqet M, Sharzehi K. Diabetes and the pancreatobiliary diseases. Curr Treat Options Gastroenterol. 2017;15:508–19.CrossRefGoogle Scholar
  33. 33.
    Tsunoda K, Kai Y, Uchida K, Kuchiki T, Nagamatsu T. Physical activity and risk of fatty liver in people with different levels of alcohol consumption: a prospective cohort study. BMJ Open. 2014;4:e005824.  https://doi.org/10.1136/bmjopen-2014-005824.CrossRefGoogle Scholar
  34. 34.
    Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS ONE. 2012;7:e53224.  https://doi.org/10.1371/journal.pone.0053224.CrossRefGoogle Scholar

Copyright information

© The Japan Diabetes Society 2019

Authors and Affiliations

  1. 1.Global Patient Safety Evaluation JapanTakeda Pharmaceutical Company LimitedOsakaJapan

Personalised recommendations